AbbVie (NYSE:ABBV) Stock Unloaded Rep. Josh Gottheimer

Posted by Brian Himes on Jun 5th, 2026

Representative Josh Gottheimer (Democratic-New Jersey) recently sold shares of AbbVie Inc. (NYSE:ABBV). In a filing disclosed on June 03rd, the Representative disclosed that they had sold between $1,001 and $15,000 in AbbVie stock on May 5th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 5/27/2026.
Purchased $1,001 – $15,000 in shares of Lumentum (NASDAQ:LITE) on 5/22/2026.
Sold $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 5/22/2026.
Purchased $1,001 – $15,000 in shares of Micron Technology (NASDAQ:MU) on 5/21/2026.
Purchased $1,001 – $15,000 in shares of Analog Devices (NASDAQ:ADI) on 5/19/2026.
Sold $1,001 – $15,000 in shares of Tri Pointe Homes (NYSE:TPH) on 5/15/2026.
Purchased $1,001 – $15,000 in shares of Palo Alto Networks (NASDAQ:PANW) on 5/14/2026.
Sold $1,001 – $15,000 in shares of Nestle (OTCMKTS:NSRGY) on 5/14/2026.
Purchased $1,001 – $15,000 in shares of Sandisk (NASDAQ:SNDK) on 5/7/2026.
Sold $1,001 – $15,000 in shares of Nestle (OTCMKTS:NSRGY) on 5/5/2026.

AbbVie Stock Up 3.5%

Shares of ABBV stock opened at $224.81 on Friday. AbbVie Inc. has a fifty-two week low of $181.73 and a fifty-two week high of $244.81. The stock has a market cap of $397.19 billion, a P/E ratio of 110.74, a P/E/G ratio of 0.66 and a beta of 0.32. The business has a fifty day simple moving average of $209.43 and a 200-day simple moving average of $219.30.

AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. During the same period in the previous year, the firm earned $2.46 EPS. The business’s revenue for the quarter was up 12.4% compared to the same quarter last year. On average, sell-side analysts anticipate that AbbVie Inc. will post 14.3 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on ABBV shares. Canaccord Genuity Group increased their price target on shares of AbbVie from $262.00 to $265.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Guggenheim reaffirmed a “buy” rating and issued a $249.00 target price on shares of AbbVie in a research note on Friday, May 1st. DZ Bank upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. Barclays initiated coverage on AbbVie in a research report on Thursday, February 19th. They set an “overweight” rating and a $275.00 price target for the company. Finally, William Blair reissued an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.43.

View Our Latest Stock Analysis on ABBV

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: AbbVie won U.K. NHS backing for Elahere, its ovarian cancer therapy, and Reuters reported the British drug-cost watchdog recommended the treatment for a hard-to-treat form of ovarian cancer, improving access and potential sales in a key market. British drug-cost watchdog recommends use of AbbVie’s ovarian cancer therapy
Positive Sentiment: The company also received European Commission approval for Aquipta to treat migraine, adding a second approved migraine indication and broadening the drug’s commercial opportunity. AbbVie receives EC approval for Aquipta to treat migraine
Positive Sentiment: Analyst coverage also highlighted AbbVie’s oncology strategy after Decnupaz approval, signaling that management is building a larger antibody-drug conjugate pipeline that could create longer-term upside. Does Decnupaz Approval Validate ABBV’s ADC Strategy in Oncology?
Neutral Sentiment: Several recent clinical-study updates, including completion of an upadacitinib study in China and a bioavailability study for ABBV-932, suggest steady pipeline progress, but they are not immediate revenue catalysts. AbbVie Completes Real World Upadacitinib Study in China: What Investors Should Watch AbbVie Advances ABBV-932 With Completed Bioavailability Study
Negative Sentiment: AbbVie also ended an early-stage lung cancer trial for ABBV-647, which trims one potential oncology growth driver and adds some caution around pipeline execution. AbbVie Ends Early Lung Cancer Trial for ABBV-647

Institutional Investors Weigh In On AbbVie

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in AbbVie by 1.7% in the 4th quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company’s stock valued at $41,306,353,000 after buying an additional 3,032,438 shares during the period. State Street Corp lifted its holdings in shares of AbbVie by 1.4% during the 4th quarter. State Street Corp now owns 80,940,931 shares of the company’s stock worth $18,494,193,000 after acquiring an additional 1,119,274 shares during the period. Geode Capital Management LLC boosted its position in shares of AbbVie by 10.4% in the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock worth $10,179,099,000 after acquiring an additional 4,190,487 shares during the last quarter. Bank of America Corp DE boosted its position in shares of AbbVie by 1.4% in the fourth quarter. Bank of America Corp DE now owns 25,824,399 shares of the company’s stock worth $5,900,617,000 after acquiring an additional 356,394 shares during the last quarter. Finally, Norges Bank purchased a new stake in AbbVie in the fourth quarter valued at approximately $5,865,055,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.

Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.

Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.

Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

About AbbVie

(Get Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.